2025-12-31
ENA first public
ERC000011
ENA-CHECKLIST
Department of Immunology, Genetics and Pathology, Cancer Precision Medicine
INSDC center name
public
INSDC status
ERS18293819
SRA accession
E-MTAB-13813:Aza 1 KMS-28PE
Submitter Id
ArrayExpress
broker name
KMS-28PE
cell_line
plasma cell
cell_type
not collected
collection date
human
common name
Protocols: INA-6, OPM2 and KMS-28PE were selected for combinatorial treatment response analysis. INA-6 and KMS28-PE cells were seeded at 100.000 cells/ml while OPM2 cells were seeded at 200.000 cells/mL 24h prior treatment with H2O and DMSO (Sigma-Aldrich) or 50nM of AZA (Abcam) and 5μM or 10μM of A366 (Tocris Bio-techne). AZA treatment was administrated every day while A366 treatment was added every 3 days. Media and reagent refreshment was performed every 3 days. All experiments were performed in three independent cell batches per cell line. RNA was extracted using the RNeasy Micro Kit (Qiagen; Hilden; Germany #74004) as described by the manufacturer. Sequencing libraries were prepared from 100ng total RNA using the Illumina Stranded Total RNA library preparation kit with Ribo-Zero Plus treatment (cat# 20040525/20040529, Illumina Inc.)
description
multiple myeloma
disease
not collected
geographic location (country and/or sea)
not applicable
isolate
Homo sapiens
organism
Homo sapiens
organism
Homo sapiens
scientific_name
Aza 200 nM
stimulus
Aza 1 KMS-28PE
title